FTSE MIB
34.481,14 -343,87 (-0,99%) Dow Jones
39.806,77 -196,82 (-0,49%) Nasdaq
16.794,88 +108,91 (+0,65%) Nikkei 225
38.946,93 -122,75 (-0,31%) Petrolio
78,73 -1,07 (-1,34%) Bitcoin EUR
65.308,48 +3.491,73 (+5,65%)
Takeda Pharmaceutical Company Limited (4502.T)
| Chiusura precedente | 4.165,00 |
| Aperto | 4.155,00 |
| Denaro | 4.132,00 x 0 |
| Lettera | 4.134,00 x 0 |
| Min-Max giorno | 4.133,00 - 4.169,00 |
| Intervallo di 52 settimane | 3.900,00 - 4.873,00 |
| Volume | |
| Media Volume | 4.272.713 |
| Capitalizzazione | 6,485T |
| Beta (5 anni mensile) | 0,54 |
| Rapporto PE (ttm) | 45,31 |
| EPS (ttm) | 91,21 |
| Prossima data utili | 31 lug 2024 |
| Rendimento e dividendo (futuro) | 196,00 (4,71%) |
| Data ex dividendo | 27 set 2024 |
| Stima target 1A | 4.814,00 |
GlobeNewswireHUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announced that Takeda (TSE:4502/NYSE:TAK) has submitted a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare (“MHLW”) in Japan for the approval of fruquintinib for the treatment of adult patients with previously
- GlobeNewswire
HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
— Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support regulatory submissions in the U.S., Europe and Japan during 2023 — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J. and OSAKA, Japan and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) and Takeda (TSE:4502, NYSE:TAK) today announced that results
